Olaparib is a prescription targeted anticancer medicine belonging to the poly (ADP-ribose) polymerase (PARP) inhibitor class. It is designed to interfere with specific mechanisms that cancer cells use to repair damaged DNA. Because some tumors have pre-existing defects in DNA-repair pathways, they may be particularly dependent on PARP-mediated repair. Blocking PARP can therefore make it more difficult for certain cancer cells to survive.
The medicine featured on Olaparib150mg.com is olaparib 150 mg. The two products specifically identified for this website are Olanib 150 mg — Everest Pharmaceuticals Ltd. and Olakin 150 mg — Ziska Pharmaceuticals Ltd. Everest’s official product catalogue identifies Olanib 150 as olaparib 150 mg, while Ziska’s official oncology information identifies Olakin as an olaparib product.
Olaparib should not be regarded as a general cancer medicine suitable for every tumor. Its clinical use is determined by the type of cancer, disease stage, previous treatment, molecular or genetic characteristics of the tumor, combination therapy where applicable, patient health and the regulatory indication relevant to the country.
What Is Olaparib?
Olaparib is an oral PARP inhibitor. PARP1 and PARP2 are enzymes involved in cellular responses to DNA damage. Cells experience DNA damage naturally and also as a consequence of environmental exposures and normal cellular processes. Several DNA-repair systems work together to maintain genomic stability.
Cancer cells frequently acquire abnormalities in these systems. In certain tumors, particularly those with defects involving BRCA1 or BRCA2, inhibition of PARP can create a significant additional repair burden.
Olaparib interferes with PARP activity and can also promote the persistence of PARP-associated DNA damage. In susceptible cancer cells, this can result in DNA damage that the cell cannot effectively repair, ultimately contributing to cancer-cell death.
This biological principle is often referred to as synthetic lethality. It helps explain why genetic or molecular testing is important for some olaparib treatment decisions.
Medicine Class
Olaparib belongs to the following pharmacological category:
| Characteristic | Information |
|---|---|
| Generic medicine | Olaparib |
| Medicine class | PARP inhibitor |
| Full class name | Poly (ADP-ribose) polymerase inhibitor |
| Therapeutic category | Targeted anticancer medicine |
| Route | Oral |
| Featured strength | 150 mg |
| Reference brand | Lynparza |
| Products featured on this website | Olanib 150 mg and Olakin 150 mg |
The 150 mg strength is an important tablet strength of olaparib. Current U.S. Lynparza labeling identifies 150 mg and 100 mg tablets.
What Is Olaparib Used For?
Olaparib has several approved uses, but the exact indications differ between regulatory jurisdictions.
Current European Medicines Agency information describes olaparib in specified treatment settings for:
- Advanced ovarian, fallopian-tube and primary peritoneal cancers
- Certain HER2-negative breast cancers associated with germline BRCA mutations
- Metastatic pancreatic adenocarcinoma associated with germline BRCA mutations
- Certain metastatic castration-resistant prostate cancers
- Selected advanced or recurrent endometrial cancers when used in combination with other medicines
Some uses involve maintenance treatment, where olaparib is administered after previous treatment has produced a response or disease control. Other treatment settings involve active therapy of advanced or metastatic disease.
The U.S. FDA labeling contains specific indications for ovarian cancer, breast cancer and BRCA-mutated metastatic castration-resistant prostate cancer, including particular combination regimens. The wording and eligibility requirements are indication-specific.
A reader should therefore never assume that an indication approved in one country is automatically approved in another.
Olaparib and BRCA Mutations
BRCA1 and BRCA2 are genes that contribute to important DNA-repair processes.
When certain cancer cells contain harmful alterations affecting BRCA-mediated DNA repair, they may become more vulnerable to medicines that inhibit PARP. This is one of the best-known examples of synthetic lethality in oncology.
However, having a BRCA mutation does not automatically mean that olaparib is appropriate. The clinical significance of a mutation depends on factors such as:
- Whether the alteration is germline or somatic
- The specific cancer type
- Disease stage
- Previous treatment
- The regulatory indication
- The testing method
- Other molecular characteristics
- The patient’s overall clinical condition
Genetic and molecular test results should therefore be interpreted by appropriately qualified healthcare professionals.
Olaparib and Homologous Recombination Deficiency
Some cancers have defects in a broader group of DNA-repair pathways collectively related to homologous recombination.
This concept is known as homologous recombination deficiency, or HRD.
HRD status may be relevant to certain treatment decisions involving PARP inhibitors, depending on the cancer type and applicable regulatory indication.
Testing strategies and eligibility criteria can differ. Patients should rely on validated testing and professional interpretation rather than attempting to determine treatment suitability from an online article.
How Does Olaparib Work?
Olaparib inhibits PARP enzymes involved in DNA damage repair.
Under normal circumstances, cells use several overlapping systems to repair DNA. If one repair mechanism is impaired, another mechanism may sometimes compensate.
Cancer cells carrying certain DNA-repair defects can become more dependent on remaining repair mechanisms. When PARP is inhibited, DNA damage can accumulate. In cells that are already deficient in homologous recombination repair, the additional damage may become difficult or impossible to tolerate.
The result can be impaired cancer-cell proliferation and cell death.
This does not mean that olaparib selectively damages only cancer cells. Normal cells also use DNA-repair mechanisms, and inhibition of PARP can contribute to adverse effects such as anemia and other blood-count abnormalities.
Why Is Olaparib Called a Targeted Therapy?
Traditional cytotoxic chemotherapy generally affects rapidly dividing cells through mechanisms that are not limited to a single molecular target.
Olaparib is different because its principal pharmacological action is directed toward PARP enzymes.
This molecular targeting does not mean that treatment is free from side effects. PARP enzymes have important biological functions in normal tissues, particularly in DNA repair and cellular maintenance.
The targeted mechanism means that treatment selection can incorporate specific biological characteristics of the cancer.
Reference Product: Lynparza
The established reference brand for olaparib is Lynparza.
Current U.S. labeling identifies Lynparza tablets as containing olaparib and lists 100 mg and 150 mg tablet strengths.
Lynparza should not automatically be equated with Olanib or Olakin. Different branded medicines containing the same active ingredient may have separate manufacturers, product documentation and regulatory pathways.
General Administration
For applicable U.S.-approved Lynparza tablet indications, the recommended adult dosage is generally 300 mg taken orally twice daily, with or without food. Two 150 mg tablets provide 300 mg for a single dose under that regimen.
However, the appropriate dose may need adjustment depending on the indication, kidney function, adverse reactions, drug interactions and other clinical circumstances.
The correct dose must always be determined by the treating healthcare professional.
Patients should not interpret the presence of a 150 mg tablet as meaning that 150 mg twice daily is appropriate for their condition.
Food Considerations
Current U.S. prescribing information permits Lynparza tablets to be taken with or without food. Patients should nevertheless follow the administration instructions accompanying their specific product and prescription.
Taking doses consistently at the prescribed times can help patients maintain an organized treatment routine.
Missed Doses
If a patient forgets a dose, they should follow the instructions in the applicable prescribing information and their healthcare professional’s advice.
Patients should not take an extra dose simply to compensate for a missed dose unless specifically instructed to do so.
Dose Modifications
Olaparib treatment may require dose interruption or reduction when significant adverse reactions occur or when certain patient factors affect drug exposure.
Dose modifications may also be required when olaparib is administered with certain medicines that affect its metabolism.
This is one reason oncology treatment should be professionally supervised rather than adjusted independently.
Important Safety Considerations
Important risks associated with olaparib include:
- Myelodysplastic syndrome and acute myeloid leukemia
- Pneumonitis
- Bone-marrow suppression and blood-count abnormalities
- Anemia
- Neutropenia
- Thrombocytopenia
- Fatigue
- Nausea and vomiting
- Potential embryo-fetal toxicity
- Drug interactions
The FDA prescribing information specifically warns about MDS/AML, pneumonitis and embryo-fetal toxicity.
Blood-Count Monitoring
Olaparib can affect bone-marrow function.
Healthcare professionals commonly monitor complete blood counts during treatment. Significant anemia, neutropenia or thrombocytopenia may require medical assessment and, depending on severity, treatment modification.
Patients should report symptoms such as:
- Persistent fever
- Unusual infections
- Unexplained bruising
- Unusual bleeding
- Severe weakness
- Increasing shortness of breath
- Pale appearance associated with significant fatigue
These symptoms do not necessarily mean a serious complication is present, but they warrant appropriate medical assessment.
Serious Long-Term Risks
MDS and AML are uncommon but important serious adverse events associated with olaparib.
The risk is particularly relevant in patients with extensive previous exposure to chemotherapy or radiotherapy, although these complications can occur in treated patients without those exact circumstances.
Persistent or unexplained blood-count abnormalities should therefore be evaluated by the treating team.
Lung-Related Safety
Pneumonitis is another important but uncommon adverse reaction.
Symptoms such as new or worsening cough, difficulty breathing, chest discomfort or unexplained respiratory symptoms should be reported promptly.
A healthcare professional can determine whether symptoms are related to olaparib, the underlying cancer, infection or another condition.
Pregnancy
Olaparib can cause fetal harm based on its pharmacological and toxicological characteristics.
Pregnancy status, reproductive plans and contraception requirements should be discussed with the healthcare team before treatment.
The FDA prescribing information provides specific recommendations concerning pregnancy and contraception for patients receiving olaparib.
Breastfeeding
Breastfeeding considerations are important because the effects of olaparib on a breastfed infant cannot be assumed to be harmless.
Patients should discuss breastfeeding with their healthcare professional before starting treatment and follow the current product-specific prescribing recommendations.
Drug Interactions
Olaparib exposure can be affected by medicines that inhibit or induce metabolic pathways involved in olaparib clearance.
Strong or moderate CYP3A inhibitors can increase olaparib exposure, while CYP3A inducers can decrease exposure. Depending on the interaction, an alternative medicine or olaparib dose adjustment may be required.
Patients should therefore provide a complete medication list to their oncology team.
What Patients Should Tell Their Healthcare Professional
Before treatment, patients should discuss:
- Previous cancer treatments
- Current medicines
- Allergies
- Kidney problems
- Previous blood disorders
- Pregnancy or pregnancy plans
- Breastfeeding
- Genetic test results
- Previous serious reactions to medicines
- Any unexplained persistent symptoms
Complete information allows the healthcare professional to assess whether olaparib is appropriate and how it should be monitored.
Olanib 150 mg — Everest Pharmaceuticals Ltd.
Olakin 150 mg — Ziska Pharmaceuticals Ltd.
These products should be distinguished from the reference brand Lynparza and should be evaluated according to their own packaging and applicable product documentation.
Olaparib can provide an important treatment option for selected patients, but it is not appropriate for every cancer or every individual. Treatment decisions should be based on the cancer diagnosis, molecular testing where required, previous therapies, organ function, potential drug interactions and the applicable regulatory indication.
The information on this website is educational and does not replace professional medical advice, diagnosis, treatment or official prescribing information.